OR WAIT null SECS
Clinical Phase Company Adopts Medidata Platform to Bring Operational Efficiencies and Greater Speed to Its Clinical Trials Across Asia
Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it has signed an enterprise agreement with ASLAN Pharmaceuticals, an oncology-focused biotechnology company. ASLAN’s adoption of the industryleading Medidata Clinical Cloud™ supports the company’s strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development in Asia.
“ASLAN is committed to transforming drug development paradigms and fundamentally changing the way serious illnesses are treated,” said Dr. Mark McHale, COO of ASLAN. “We selected the Medidata Clinical Cloud as our enterprisewide technology platform because it is helping us bring greater speed and efficiency to clinical trials. With its broad adoption across Asia, the Medidata platform allows us to be more creative, agile and efficient, while ensuring investigator engagement in our studies.”
With offices in Singapore and Taiwan, ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies and leverages high-quality, innovative clinical centers in Asia to advance drug development. In support of this work, ASLAN is using Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and randomization and supply management (Medidata Balance®).
“We’re thrilled ASLAN is using the Medidata platform to conduct early clinical studies in areas of significant unmet needs,” said Glen de Vries, Medidata’s president. “We share ASLAN’s vision of transforming clinical development, so that innovative new medicines can be delivered to patients faster and with lower cost and risk.”
Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region, said, “The life science industry is growing in APAC, allowing for more and more business opportunities. I am honored that Medidata’s technology is helping this emerging market execute better trials to produce innovative drugs for the rest of the world.”